NAYA Biosciences Common Stock Other Current Liabilities

As of the most recent data (March 2026), IVF shows a other current liabilities of $3.2B. That compares with $12B in the prior-year period — down 73.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IVF's other current liabilities is now $3.2B (was $12B) — a 73.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether NAYA Biosciences Common Stock is outperforming or lagging.

Tracking IVF's other current liabilities over time shows whether NAYA Biosciences Common Stock is scaling, shrinking, or reshaping that part of the business. The current reading is $3.2B That compares with $12B in the prior-year period — down 73.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has NAYA Biosciences Common Stock's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $3.2B) with ownership activity and broader fundamentals.

NAYA Biosciences Common Stock's other current liabilities is $3.2B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.